Behnaz Saidy
PP1, PKA and DARPP-32 in breast cancer: a retrospective assessment of protein and mRNA expression
Saidy, Behnaz; Kotecha, Shreeya; Butler, Anna; Rakha, Emad; Ellis, Ian; Green, Andrew; Martin, Stewart; Storr, Sarah
Authors
Shreeya Kotecha
Anna Butler
Professor EMAD RAKHA Emad.Rakha@nottingham.ac.uk
PROFESSOR OF BREAST CANCER PATHOLOGY
Ian Ellis
Dr Andy Green ANDREW.GREEN@NOTTINGHAM.AC.UK
ASSOCIATE PROFESSOR
Professor STEWART MARTIN STEWART.MARTIN@NOTTINGHAM.AC.UK
PROFESSOR OF CANCER AND RADIATION BIOLOGY
Dr SARAH STORR sarah.storr@nottingham.ac.uk
ASSISTANT PROFESSOR
Abstract
Cyclic-AMP dependent protein kinase A (PKA) and protein phosphatase 1 (PP1) are proteins involved in numerous essential signalling pathways that modulate physiological and pathological functions. Both PP1 and PKA can be inhibited by dopamine and cAMP regulated phosphoprotein 32kDa (DARPP-32). Using immunohistochemistry, PKA and PP1 expression was determined in a large primary breast tumour cohort to evaluate associations with clinical outcome and clinicopathological criteria (n>1100). In addition, mRNA expression of PKA and PP1 subunits was assessed in the METABRIC dataset (n=1980).
Low protein expression of PKA was significantly associated with adverse survival of breast cancer patients; interestingly, this relationship was stronger in ER positive breast cancer patients. PP1 protein expression was not associated with patient survival. PKA and PP1 subunit mRNA was also assessed; PPP1CA, PRKACG and PRKAR1B were associated with breast cancer specific survival.
In patients with high expression of DARPP-32, low expression of PP1 was associated with adverse survival when compared to high expression in the same group. PKA and PP1 expression are of significant interest in cancer as they are involved in a wide array of cellular processes and this data indicates PKA and PP1 may play an important role in patient outcome.
Citation
Saidy, B., Kotecha, S., Butler, A., Rakha, E., Ellis, I., Green, A., Martin, S., & Storr, S. (2021). PP1, PKA and DARPP-32 in breast cancer: a retrospective assessment of protein and mRNA expression. Journal of Cellular and Molecular Medicine, 25(11), 5015-5024. https://doi.org/10.1111/jcmm.16447
Journal Article Type | Article |
---|---|
Acceptance Date | Feb 24, 2021 |
Online Publication Date | May 15, 2021 |
Publication Date | 2021-06 |
Deposit Date | Jun 22, 2021 |
Publicly Available Date | Jun 25, 2021 |
Journal | Journal of Cellular and Molecular Medicine |
Print ISSN | 1582-1838 |
Electronic ISSN | 1582-4934 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 25 |
Issue | 11 |
Pages | 5015-5024 |
DOI | https://doi.org/10.1111/jcmm.16447 |
Public URL | https://nottingham-repository.worktribe.com/output/5361498 |
Publisher URL | https://onlinelibrary.wiley.com/doi/10.1111/jcmm.16447 |
Files
PP1, PKA and DARPP-32 in breast cancer
(1.1 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
The role of the ALKBH5 RNA demethylase in invasive breast cancer
(2024)
Journal Article
Epitranscriptomic mechanisms of androgen signalling and prostate cancer
(2024)
Journal Article
Stromal lymphocytes are associated with upgrade of B3 breast lesions
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search